Why is "CDK4" trending?

Search Interest Perspective

• 108 Long-Term Safety and Efficacy of First-Line Next Generation CDK4-Selective Inhibitor Atirmociclib + Letrozole for the Treatment of Patients With HR+/HER2− Metastatic Breast Cancer - CancerNetwork
• Who Benefits From Ribociclib? NATALEE Insights From ASCO 2026 - Docwire News
• ASCO26: 'Blunting' effect of CDK4/6 inhibitor may have downed Roche's persevERA study of oral SERD - FirstWord Pharma
• CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53 -mutant clonal hematopoiesis - Nature
• Lymph Node Surgery and CDK4/6 Inhibitor Treatment in Early Breast Cancer - The ASCO Post
• Study reveals synergistic effect of CDK2 and CDK4/6 combination therapy - UT MD Anderson
• Camizestrant Plus CDK4/6 Inhibitor Demonstrates Sustained Benefit Beyond First Progression in ESR1-Mutated Breast Cancer - Pharmacy Times
• CDK4/6 inhibitors are changing breast cancer treatment - Mayo Clinic Press
• Earlier Use of CDK4/6 Inhibitors, Oral SERDs Reflects Shift Toward Proactive Management of HR+ Breast Cancer - OncLive
• Genome-wide screenings identify BAP1 as a synthetic-lethality target with CDK4/6 inhibitors - Science | AAAS
• Beyond efficacy: CDK4/6 inhibitors in metastatic breast cancer - The Lancet
• CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction - Nature
• CHMP Recommends Camizestrant Plus CDK4/6 Inhibitor for ESR1-Mutated HR+ Advanced Breast Cancer - OncLive
• What’s Next After CDK4/6? Navigating Second‑Line and Mutation‑Driven Therapies - Docwire News
• ASCO Collaborates With Ryght AI to Accelerate Site Selection for Metastatic Breast Cancer Trial - The ASCO Post
• CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen - Nature
• RSK Inhibition Is Poised for Deeper Activity in RSK-High, CDK4/6 Inhibitor–Resistant Breast Cancer - OncLive
• TGFβ signaling promotes cell cycle progression and resistance to the CDK4/6 inhibitor palbociclib through SOX4 transcriptional modulation in breast cancer cells | Cell Death & Disease - Nature
• Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations - Nature
• Inactivation of CDK4/6, CDK2, and ERK in G1-phase triggers differentiation commitment - Nature
• Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer - Science | AAAS
• ZDHHC17-Mediated CDK4 Palmitoylation Drives Cell Cycle Progression and Orchestrates Cancer Immune Surveillance - Wiley
• How Next-Generation CDK Inhibitors Are Redefining Post–CDK4/6 Therapy in HR+/HER2– Metastatic Breast Cancer - Pharmacy Times
• Pfizer’s oral CDK4 inhibitor shows promise in second-line breast cancer - Clinical Trials Arena
• Temporal control of human DNA replication licensing by CDK4/6-RB signalling and chemical genetics - Nature
• When in Breast Cancer Treatment Are CDK4/6 Inhibitors Best? - Medscape
• Alpelisib Plus Fulvestrant Hits Primary PFS End Point in CDK4/6 Inhibitor–Pretreated, PIK3CA-Mutant, HR+/HER2– Breast Cancer - OncLive
• 124 Real-World Progression-Free Survival 2 and Tumor Response of CDK4/6is + Aromatase Inhibitor in Patients With HR+/HER2– Metastatic Breast Cancer - CancerNetwork
• CDK4/6 Inhibitors in Advanced Breast Cancer: Is Sooner Really Better? - AJMC
• TIP 129 The Role of Vitamin D in CDK4/6 Inhibitor Therapy for Breast Cancer - CancerNetwork
• Germline BRCA2 mutations foster resistance to CDK4/6 inhibitors in breast cancer - Nature
• CDK4/6 Inhibitor Bireociclib Improves Progression-Free Survival in Advanced Breast Cancer - AJMC
• TIP103 Randomized Phase 3 Clinical Trial Evaluating Atirmociclib Plus Letrozole Versus a CDK4/6 Inhibitor Plus Letrozole as First-Line Treatment for Patients With HR+/HER2− Advanced/Metastatic Breast Cancer - CancerNetwork
• Camizestrant Switch Plus CDK4/6 Inhibition Continues to Outperform SOC in HR+/HER2– Breast Cancer - OncLive
• γδ T cells and resistance to CDK4/6 inhibitors in breast cancer - Nature
• Abemaciclib Monotherapy Shows Efficacy After CDK4/6 Inhibition in HR+/HER2– Breast Cancer - OncLive
• Predicting Breast Cancer Behavior Under Therapeutic Pressure: Hemizygosity and HRD Drive Resistance to CDK4/6 inhibitors in Breast Cancer - Memorial Sloan Kettering Cancer Center
• Sequential CDK4/6 inhibition in bone-only metastatic HR+/HER2- breast cancer: a case of prolonged disease control with abemaciclib after clinical progression on palbociclib-based therapy - Frontiers
• No Survival Benefit in Advanced Breast Cancer With Frontline CDK4/6 Inhibition - MedPage Today
• Regulation of the immune CD155–CD226–TIGIT axis by cyclin D-CDK4/6 - PNAS
• 107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-B - CancerNetwork
• 104 KATSIS-1: Randomized Phase 3 Trial Evaluating KAT6 Inhibitor PF-07248144 (prifetrastat) Plus Fulvestrant in HR+HER2− Advanced/Metastatic Breast Cancer After Progression on CDK4/6 Inhibitor-Based Therapy - CancerNetwork
• ZDHHC17-Mediated CDK4 Palmitoylation Drives Cell Cycle Progression and Orchestrates Cancer Immune Surveillance - Wiley
• Targeting CDK4/6 and mTORC1 in Translocation Renal Cell Carcinoma - CancerNetwork
• Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer - Targeted Oncology
• Combined CDK4/6 and EGFR inhibition improves pancreatic cancer therapy - News-Medical
• Emerging Data With Oral SERDs Reframe Frontline and Post–CDK4/6 Decisions in ER+ Breast Cancer - OncLive
• The SONIA trial: redefining “better” in the sequencing of CDK4/6 inhibitors for advanced breast cancer - Frontiers
• Evolving Post–CDK4/6 Inhibitor Strategies Reflect Need for Precision Approaches in HR+ Breast Cancer - OncLive
• Preventing breast cancer resistance to CDK4/6 inhibitors using genomic findings - Medical Xpress
• Long-term phase III data reinforce the benefits of CDK4/6 inhibitors in early breast cancer - ESMO Daily Reporter
• CDK4/6 Inhibitor Sequencing in the Metastatic Setting and Maintenance Strategies Following THP Induction - OncLive
• Bridging Evidence and Care: CDK4/6 Inhibitor Management After Landmark Trial Success - Medscape
• Targeted Combos and ADCs Show Benefit After CDK4/6 in HR+/HER2− mBC - Docwire News
• FOURLIGHT-1 Study of Atirmociclib in Second-Line Metastatic Breast Cancer Yields Positive Results - Docwire News
• T Cell Antitumor Immunity via MIF-Induced Functional Orchestration of Tumor-Associated Macrophages - Wiley
• Behind the Science: A New Path to Tackling Metastatic Breast Cancer - Pfizer
• Treatment Selection Post–CDK4/6 Inhibition in Advanced ER+ Breast Cancer - OncLive
• IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer - Nature
• Dr Callahan on the Use of CDK4/6 Inhibitors Plus Endocrine Therapy in Breast Cancer - OncLive
• Impact of Pharmacist-Driven Oral Chemotherapy Treatment Plan Implementation on Monitoring and Supportive Care Interventions During CDK4/6 Inhibitor Therapy for Patients With Breast Cancer - Journal of Hematology Oncology Pharmacy
• Your CDK4/6 Inhibitor Treatment Cycle for Metastatic Breast Cancer: A Practical Guide - Everyday Health
• CDK4/6 Inhibition Preserves Multiple Cell Lines in SCLC - Targeted Oncology
• Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study - Business Wire
• Optimal HR+ Early Breast Cancer Care Must Weigh CDK4/6 Inhibitor Efficacy With Adherence - OncLive
• Camizestrant Plus CDK4/6 Inhibition Causes Minimal Effect on Visual QOL in HR+, ESR1-Mutated Breast Cancer - OncLive
• Pfizer's hotly tipped breast cancer prospect records phase 2 win - Fierce Biotech
• HR+/HER2- breast cancer on CDK4/6 inhibitors: AI-supported home management improves psychosocial outcomes - Vera Health
• Highlights from BGICC 2026: Overcoming CDK4/6 Inhibitor Resistance in ER+/HER2-Negative Breast Cancer — Insights from Giuseppe Curigliano - Oncodaily
• The Role of CDK4/6 Inhibitors in ER-Positive, HER2-Negative Metastatic Breast Cancer - Cure Today
• PACE II Trial Highlights ctDNA Biomarkers to Guide Post-CDK4/6 Therapy in Metastatic HR+/HER2– Breast Cancer - Docwire News
• Advancing Treatment After CDK4/6 Inhibitor Progression in HR+/HER2– Breast Cancer - Pharmacy Times
• Avenzo Therapeutics Advances the Combination of CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) in Ongoing Phase 1/2 ORION-1 Study in HR+/HER2- Breast Cancer - Business Wire
• Optimizing CDK4/6 Inhibitor Use: Dosing, Safety, and Pharmacist Management - Pharmacy Times
• Giredestrant-Based Combo Boosts PFS Across Subgroups in Advanced ER+/HER2– Breast Cancer After CDK4/6 Inhibition - OncLive
• Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines - Nature
• Adjuvant CDK4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer - Cancer Therapy Advisor
• Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study - Yahoo Finance
• HR+/HER2- breast cancer on CDK4/6 inhibitors: AI-supported home management improves psychosocial outcomes - Vera Health
• CDK4/6 Inhibition With Palbociclib Displays Activity in Low-Grade Serous Ovarian Cancer - OncLive
• ‘Why do we do this?’: Sooner not better for CDK4/6 inhibitors in advanced breast cancer - Healio
• Second-Line CDK4/6i Cost-Effective in Breast Cancer - Medscape
• CDK4/6 inhibition with dual immunotherapy in chemorefractory SMARCA4-deficient undifferentiated tumor: a case report - Frontiers
• IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR - Nature
• Pfizer’s Ibrance successor moves forward with new study data - BioPharma Dive
• Biotheryx Announces Data from its Phase 1 Dose Escalation Study of BTX-9341, a First-in-Class, Potent and Selective CDK4/6 Degrader, for the Treatment of Advanced/Metastatic HR+/HER2- Breast Cancer - PR Newswire
• SONIA Trial Challenges Routine First-Line CDK4/6 Use in Advanced Breast Cancer - Oncodaily
• Treatment Sequencing and Patient Adherence With CDK4/6 Inhibitors - Pharmacy Times
• CDK4/6 Inhibitors Moving Into Early-Stage Breast Cancer is a “Huge Advance” - CancerNetwork
• CDK4/6 Inhibitors in Metastatic Breast Cancer: Approvals and Clinical Considerations - Pharmacy Times
• Sequencing Endocrine and Targeted Therapies After CDK4/6 Inhibitor in ESR1-Mutant Breast Cancer Progression - OncLive
• CDK inhibitors show wider cancer potential as combinations and biomarkers advance - Medical Xpress
• TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy - CancerNetwork
• Supporting Complex Breast Cancer Care Through Pharmacist Expertise and CDK4/6 Inhibitors - Pharmacy Times
• BRCA2-Driven Breast Cancer May Follow A Different Resistance Path On CDK4/6 Inhibitors - Oncodaily
• Adjuvant CDK4/6 Inhibitors Gain Ground as Oral SERDs Emerge to Tackle Endocrine Resistance in Early HR+ Breast Cancer - OncLive
• TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Tr - CancerNetwork
• Dose Reductions and Escalations With CDK4/6 Inhibitors - Pharmacy Times
• FDA-Approved CDK4/6 Inhibitors for Early and Metastatic Breast Cancer - Pharmacy Times
• Second-Line Treatment Options in Metastatic Breast Cancer After AI Plus CDK4/6 Inhibitor - Oncodaily